PROK earnings: next report 2026-08-11, real EPS beat/miss history, analyst consensus Buy, P/E -2.78. Updated 2026-07-23.
ProKidney (PROK) Research Hub
ProKidney (PROK) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 1.8 USD (-2.70%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -2.78, market cap 0.52B. This hub links to the full technical, earnings and options research available for PROK.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 1.8 USD (-2.70%) |
| 52-week range | 1.31 USD – 2.24 USD |
| Trend regime | Range |
| 14-day RSI | 57.5 (Bullish) |
| Trailing P/E | -2.78 |
| Market cap | 0.52B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-11 |
Available research for PROK
Covered Call on PROK: how it works, illustrative setup around the real 1.8 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on PROK: how it works, illustrative setup around the real 1.8 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on PROK: how it works, illustrative setup around the real 1.8 USD price, max profit/loss, breakeven and when to use it. Educational.
PROK technical analysis: range, last 1.8 USD, RSI 57.5, 52w range 1.31 USD–2.24 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is PROK in?
ProKidney (PROK) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is PROK in an uptrend or downtrend?
As of 2026-09-11, PROK is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is PROK's trailing P/E ratio?
PROK's trailing P/E is -2.78, with a market cap of 0.52B. See the earnings research page for full valuation detail.
When does PROK next report earnings?
PROK is next scheduled to report earnings on 2026-08-11, with a consensus EPS estimate of -0.13 USD.